Clinical observation of apatinib in the treatment of metastatic colorectal cancer
CHEN Zhu, LIU Yan, GAO Li-hua, CHEN Bu-you, TANG Ai-hua, LIU Jun · 2021 · Jichu yixue yu linchuang
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
Objective To evaluate the efficacy and safety of apatinib in the treatment of metastatic colorectal cancer (mCRC). Methods Sixty-five patients with mCRC treated with apatinib were enrolled in this study for retrospective analysis. The factors affecting the recent effective, progression-free survival (PFS) and adverse reactions were evaluated. Results The disease control rate in 63 evaluable patients was 69.9%. The median PFS for patients received first-line, second-line, and third-line and above apatinib treatment were 9.3 months, 5.8 months, and 3.3 months, respectively(P＜0.001). The PFS in t
Abstract by CHEN Zhu, LIU Yan, GAO Li-hua, CHEN Bu-you, TANG Ai-hua, LIU Jun, Jichu yixue yu linchuang (2021) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Negative / Null Result ReportDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
Negative / Null Result ReportStenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
Negative / Null Result ReportEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Replication FailureA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Negative / Null Result ReportSpironolactone for Heart Failure with Preserved Ejection Fraction
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: DOAJ